healthcare stocks Archives

Alt Text: Illustration of the Nobel Prize in Medicine lighting a new bull market for brain science, featuring a glowing brain, neural connections, a rising stock-market chart and a charging digital bull above a city skyline as researchers look on.

Nobel Prize in Medicine Illuminates a New Bull Market for Brain Science -( $BIIB $DHR $GSGTF $ILMN $IRD $MLPT $NBIX $OCGN $REGN $TMO )

by John F. Heerdink, Jr. 5 minutes ago 14Views 0Likes

The 2026 Nobel Prize in Physiology or Medicine has put optogenetics, the science of using light to control precisely selected nerve cells, squarely in the global spotlight. For many, the award is more than a ceremonial victory lap for academic neuroscience:…

Illustration of a glowing green Nasdaq-themed cobra rising beside upward stock-market charts on a trading floor, representing the October 5, 2026 technology-led market rally as investors look past higher Treasury yields and a cautious bond market.

Stock Market Today, October 5, 2026: Nasdaq Leads Rally as Tech Ignores Bond-Market Side-Eye -( $AMWL $AZN $DOCS $EPRX $LPL $MODD $NVDA $SER $SMMT $SPCX $TSLA $TSM )

by John F. Heerdink, Jr. 2 hours ago 144988Views 0Likes

NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.

The Biotech IPO Window Is Open, and Parabilis Medicines Walked Through With $770 Million -( $ADRX $BRVE $ETRA $KLRA $JNJ $PBLS $REGN )

by John F. Heerdink, Jr. 2 days ago 224Views 0Likes

Parabilis Medicines, Inc. (NASDAQ: PBLS) entered public markets with the kind of financial runway, strategic endorsement and clinical ambition that tends to make biotech investors sit up straighter in their Aeron chairs. The Cambridge-based clinical-stage company is pursuing a deceptively simple proposition: use…

Comic-book-style illustration highlighting pharma, space and AI investment themes: a Bayer research lab in Ohio, a SpaceX rocket launching from an Ohio-inspired Starbase, and Eupraxia displayed over an AI-powered global network, beneath the headline “Pharma, Rockets and AI: Why Bayer, SpaceX and Eupraxia Have Investors Looking Up.”

Pharma, Rockets and AI: Why Bayer, SpaceX and Eupraxia Have Investors Looking Up -( $BAYRY $EPRX $GOOGL $SPCX $TSLX )

by John F. Heerdink, Jr. 3 days ago 167Views 0Likes

The Market’s Growth Engines Are Getting Physical Wall Street has spent years rewarding promises around artificial intelligence, advanced medicine and space infrastructure. This week, the narrative acquired something investors usually appreciate even more: concrete evidence of execution. Bayer AG (OTC: BAYRY) is…

Business analysts review Eupraxia Pharmaceuticals’ EP-104GI clinical data, including symptom reduction and histological-response visuals, alongside an investment calendar highlighting the anticipated December 2026 RESOLVE trial milestone.

Eupraxia’s One-Year EoE Data Draw Fresh Analyst Attention Ahead of December Catalyst – ( $EPRX $IBB $SNY $XBI )

by John F. Heerdink, Jr. 3 days ago 358Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a new layer of clinical durability to its EoE investment case, and Wall Street’s bullish coverage is becoming harder to overlook. The company’s latest 52-week EP-104GI data, including 64% clinical remission among evaluable higher-dose…

Cartoon-style Wall Street trading floor scene featuring a smiling bull in a pinstripe suit holding a phone with a rising green chart, surrounded by applauding traders, confetti and market screens highlighting cooling inflation, booming AI demand, consumer resilience and an advancing S&P 500.

Cooling Inflation, AI Demand and Consumer Resilience: Why Wall Street’s Bull Case May Be Getting Stronger -( $AAPL $AMZN $CVS $ELV $MCD $NVDA $SKHY $UNH )

by John F. Heerdink, Jr. September 30, 2026 295Views 0Likes

A steadier labor market, cooler-than-expected inflation, fresh consumer purchasing power, evolving digital-advertising models and disciplined corporate cost management are creating a more constructive backdrop for equities. The economy is not behaving like a fireworks display, but for investors that may be the…

Promotional graphic for a Tribe Public CEO dinner event featuring Eupraxia Pharmaceuticals (NASDAQ: EPRX), James Helliwell, M.D., and the company’s 52-week EP-104GI clinical update for eosinophilic esophagitis. The image illustrates localized treatment at week zero, durable symptom control through week 52, and a stylized upward EPRX market graphic.

Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI )

by John F. Heerdink, Jr. September 30, 2026 330Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a potentially important chapter to its eosinophilic esophagitis, or EoE, story: a single administration of its investigational localized therapy, EP-104GI, continued to show clinical-remission signals at 52 weeks in the highest-dose cohorts of the…

Iovance Biotherapeutics revenue guidance display in a modern trading-floor setting, highlighting rising Amtagvi demand, a Goldman Sachs Buy rating, and NASDAQ market screens.

Iovance Biotherapeutics Raises 2026 Revenue Guidance as Amtagvi Demand Accelerates & Goldman Resumes Coverage – ( $GS $IOVA $XBI $IBB )

by John F. Heerdink, Jr. September 30, 2026 342Views 0Likes

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) delivered the sort of update growth investors prefer: higher guidance, record revenue, expanding treatment access, and a more visible route toward operating leverage. Shares climbed sharply after the company lifted its 2026 revenue outlook, suggesting Wall Street is…

Illustration of a futuristic biotech bear in a forest alongside a princess and armored knight, symbolizing the growing investment opportunity in durable drug-delivery therapies for retinal disease, eosinophilic esophagitis, and Parkinson’s disease.

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

by John F. Heerdink, Jr. September 28, 2026 403Views 0Likes

The biotech market has long rewarded breakthrough efficacy. Increasingly, it is also rewarding something patients and physicians understand with unusual clarity: less treatment burden. Fresh clinical updates from Kodiak Sciences Inc. (NASDAQ: KOD), Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), and Serina Therapeutics Inc. (NYSE…

Illustrated weekly market summary for September 25, 2026, showing a glowing green bull and rising stock chart on the left, oil pumpjacks and pipelines in the center labeled “Oil Pullback,” and a bridge made of U.S. dollar bills on the right, representing higher U.S. equities, lower crude prices and ongoing macroeconomic uncertainty.

Weekly Market Summary (Sept. 25, 2026): Stocks Gain as Oil Pullback Eases Pressure, While Treasury Yields Stay Elevated -( $AKAM $AMWL $DOCS $LPL $META $MODD $MSFT $NVDA $SER $YSG )

by John F. Heerdink, Jr. September 25, 2026 84676Views 0Likes

NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.

Tag: healthcare stocks

Nobel Prize in Medicine Illuminates a New Bull Market for Brain Science -( $BIIB $DHR $GSGTF $ILMN $IRD $MLPT $NBIX $OCGN $REGN $TMO )

Stock Market Today, October 5, 2026: Nasdaq Leads Rally as Tech Ignores Bond-Market Side-Eye -( $AMWL $AZN $DOCS $EPRX $LPL $MODD $NVDA $SER $SMMT $SPCX $TSLA $TSM )

The Biotech IPO Window Is Open, and Parabilis Medicines Walked Through With $770 Million -( $ADRX $BRVE $ETRA $KLRA $JNJ $PBLS $REGN )

Pharma, Rockets and AI: Why Bayer, SpaceX and Eupraxia Have Investors Looking Up -( $BAYRY $EPRX $GOOGL $SPCX $TSLX )

Eupraxia’s One-Year EoE Data Draw Fresh Analyst Attention Ahead of December Catalyst – ( $EPRX $IBB $SNY $XBI )

Cooling Inflation, AI Demand and Consumer Resilience: Why Wall Street’s Bull Case May Be Getting Stronger -( $AAPL $AMZN $CVS $ELV $MCD $NVDA $SKHY $UNH )

Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI )

Iovance Biotherapeutics Raises 2026 Revenue Guidance as Amtagvi Demand Accelerates & Goldman Resumes Coverage – ( $GS $IOVA $XBI $IBB )

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

Weekly Market Summary (Sept. 25, 2026): Stocks Gain as Oil Pullback Eases Pressure, While Treasury Yields Stay Elevated -( $AKAM $AMWL $DOCS $LPL $META $MODD $MSFT $NVDA $SER $YSG )

Your Guide To Staying Informed In The Markets